A decision aid to help breast cancer patients make chemotherapy choices
CIPN Decision Aid to Improve Neurotoxic Chemotherapy Decision Making
This study tests a smartphone tool to help breast cancer patients who have nerve pain from chemotherapy make better choices about their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT06915168 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a decision aid designed to improve chemotherapy decision-making for patients with breast cancer who are experiencing chemotherapy-induced peripheral neuropathy (CIPN). The decision aid provides information about the potential long-term effects of CIPN, helping patients understand their treatment priorities and facilitating discussions with their oncologists. Patients currently receiving taxane treatment and experiencing symptoms of CIPN will participate in the study, utilizing a smartphone-based tool to access the decision aid. The goal is to enhance patient awareness and decision-making regarding their chemotherapy options.
Who should consider this trial
Good fit: Ideal candidates for this study are breast cancer patients currently undergoing taxane treatment and experiencing symptoms of CIPN.
Not a fit: Patients who are not experiencing any symptoms of CIPN or those unable to read or speak English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could empower breast cancer patients to make more informed decisions about their chemotherapy treatment, potentially improving their quality of life.
How similar studies have performed: Previous studies have indicated that decision aids can improve patient understanding and decision-making in similar contexts, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with breast cancer * Currently receiving cycle three of taxane treatment * Approval of medical oncologist to enroll patient * Experiencing any CIPN based on enrollment screening question, "In the last 7 days, what was the severity of your numbness or tingling in your hands or feet at its worst? None, Mild, Moderate, Severe, Very Severe. Patient is eligible if their answer is anything except "None" * Access to a smartphone or similar device that can complete CIPN DecisionAid via Qualtrics while in the waiting room Exclusion Criteria: * Inability to read or speak English
Where this trial is running
Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Daniel L Hertz — University of Michigan Rogel Cancer Center
- Study coordinator: Daniel Hertz
- Email: DLHertz@med.umich.edu
- Phone: 734-763-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.